scout
News|Videos|September 10, 2025

Elacestrant Combinations in ER+/HER2- Locally Advanced or Metastatic Breast Cancer: Efficacy and Safety Updates from the Phase 1b/2 ELEVATE Study

Presented by Dr. Hope S. Rugo, this slide deck presents updated phase 1b/2 safety and efficacy results from the ELEVATE trial of elacestrant combinations with ribociclib and everolimus in ER+/HER2- metastatic breast cancer, highlighting their clinical activity and potential as an endocrine therapy backbone.

Funding supported by Stemline Therapeutics. Content independently developed by OncLive

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME